Adam Feuerstein from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 8 days ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - about 2 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - about 2 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 2 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 3 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 3 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 4 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 4 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 4 months ago Listen: Drug pricing drops & psychedelics under fire - 4 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 5 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 5 months ago
2	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 8 days ago Pfizer’s new R&D head, a VC deep-dive, and a new FDA commissioner? - 29 days ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - about 2 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - about 2 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 2 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 3 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 3 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 4 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 4 months ago Listen: Drug pricing drops & psychedelics under fire - 4 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 5 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 5 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 7 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 8 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 8 months ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - 9 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 9 months ago Listen: Live! From the STAT Breakthrough Summit East - 9 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 9 months ago
3	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children - 8 days ago STAT+: Investors in Padlock Therapeutics sue Bristol Myers Squibb over ‘milestone’ payments - 8 days ago STAT+: Biotech companies detail emerging efforts to ease ‘conditioning’ before genetic treatments - 11 days ago Biopharma leaders lay out vision for the future of blood cancer treatment - 12 days ago Sanofi advances a drug for a rare, platelet-destroying disease - 13 days ago Roche’s TIGIT troubles continue, a novel Alzheimer’s target misses the mark, and other biotech news - 24 days ago Pfizer’s new R&D head, a VC deep-dive, and a new FDA commissioner? - 29 days ago STAT+: The state of biotech M&A 2024 - 29 days ago STAT+: Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit - about 2 months ago STAT+: Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment - about 2 months ago Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - about 2 months ago Pfizer’s activist troubles, gene therapy questions, RFK Jr.’s MAHA ambitions - about 2 months ago STAT+: Study on Sarepta Therapeutics’ Duchenne therapy diverges from the company line - about 2 months ago STAT+: Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores - about 2 months ago STAT+: Perplexing results from Duchenne muscular dystrophy trial raise questions about gene therapies - 2 months ago Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - 2 months ago STAT+: Pharmalittle: We’re reading about an Italian acquisition, Medicare Advantage market growth, and more - 3 months ago Biden’s health care AI czar, a new obesity company, and its dealmaking CEO - 3 months ago A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids - 3 months ago STAT+: Can iTeos and GSK solve TIGIT’s troubles? - 3 months ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 4 months ago STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal - 4 months ago STAT+: Alnylam versus BridgeBio: The ATTR-CM debate - 4 months ago Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides - 4 months ago STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more - 4 months ago STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 4 months ago Listen: Drug pricing drops & psychedelics under fire - 4 months ago Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates - 5 months ago STAT+: On Andrew Left and the government’s fraud case - 5 months ago STAT+: Sage suffers pipeline setback with failure of drug to treat essential tremor - 5 months ago STAT+: With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer’s disease world - 5 months ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 5 months ago STAT+: Roche’s TIGIT study was a bust. What’s the outlook for its next big bet? - 5 months ago A biotech’s binary bet ends badly - 6 months ago STAT+: Pharmalittle: We’re watching more positive data for Ozempic, a Lilly factory expansion, and more - 7 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 7 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 8 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 8 months ago STAT+: The inside story of Enhertu’s pan-tumor approval - 8 months ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - 9 months ago STAT+: Weed for weight loss, and more from Biotech Land - 9 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 9 months ago STAT+: A contrarian view on Viking Therapeutics, biotech’s hottest obesity stock - 9 months ago Listen: Live! From the STAT Breakthrough Summit East - 9 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 9 months ago STAT+: Madrigal wins first U.S. approval for drug to treat liver disease MASH - 9 months ago STAT+: First medicine developed to treat MASH expected to be approved soon - 9 months ago STAT+: Acadia’s Nuplazid fails as treatment for schizophrenia in Phase 3 study - 9 months ago STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next - 10 months ago STAT+: In stunning outcome, Amylyx’s ALS drug fails large clinical trial - 10 months ago
4	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	Biopharma leaders lay out vision for the future of blood cancer treatment - 12 days ago Sanofi advances a drug for a rare, platelet-destroying disease - 13 days ago
5	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Biopharma leaders lay out vision for the future of blood cancer treatment - 12 days ago
6	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	Biopharma leaders lay out vision for the future of blood cancer treatment - 12 days ago
7	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment - about 2 months ago STAT+: Perplexing results from Duchenne muscular dystrophy trial raise questions about gene therapies - 2 months ago
8	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: What to know about Alnylam’s upcoming readout on its heart drug - 4 months ago
9	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 8 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 9 months ago Listen: Live! From the STAT Breakthrough Summit East - 9 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 9 months ago STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next - 10 months ago